Concerning PD-L1, our data highlighted that a sizeable fraction of early-stage NSCLC (16.5%, see Table 2) expressed PD-L1 within the threshold values currently used to assign patients with advanced-stage NSCLC to therapy with immune checkpoint inhibitors. The gene discussed is CD274; the disease is non-small cell lung carcinoma.